The Pharmaceutical Journal
Vol 280 No 7501 p556
10 May 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

MHRA safety update

Safety profiles of the anti-obesity drug rimonabant (Acomplia) and the incretin mimetic exenatide (Byetta) are the focus of May 2008’s Drug Safety Update published by the Medicines and Healthcare products Regulatory Agency.

The MHRA reminds prescribers of the psychiatric adverse reactions associated with rimonabant and the risk of acute pancreatitis with exenatide.